Abstract
| Grant Number: | 5R44DK066654-04 |
| Project Title: | Kidney Preservation for Transplantation |
| PI Information: | Name | Email | Title |
| CAI, WEIZHONG |
wcai@angion.com |
PRINCIPAL INVESTIGATOR |
Abstract:
DESCRIPTION (provided by applicant): Renal transplantation is the most effective and cost-efficient treatment for patients in end-stage kidney failure. However ischemia-reperfusion injury, associated with the retrieval, storage and transplantation of kidneys is a major immune-independent factor adversely affecting early graft function and graft viability. Marginal donors kidneys, are even more susceptible to ischemia-reperfusion injury, and often fail transplantation. Scatter factor/hepatocyte growth factor is a renal trophic factor with significant renooprotective activity. However its clinical use is limited by the logistical difficulties associated with its administration. We have identified Refanalin, an organic small molecule scatter factor/hepatocyte growth factor mimetic, with significant cytoprotective activity. In in vivo models of renal ischemia-reperfusion injury, Refanalin attenuated cell death and improved renal function. In an in vivo model of renal transplantation, Refanalin treatment attenuated mortality, improved graft function and preserved graft viability. The present Phase II proposal explores the therapeutic potential of Refanalin in clinically relevant models of optimal, marginal and large animal renal transplantation. By attenuating allograft dysfunction and preventing allograft failure, Refanalin can reduce recipient morbidity and mortality. By attenuating ischemia-reperfusion injury in the marginal kidney, Refanalin can salvage an otherwise discarded organ, and increase the donor pool.
Thesaurus Terms:
analog, drug screening /evaluation, hepatocyte growth factor, histocompatibility, kidney transplantation, postoperative complication, reperfusion, small molecule, transplant rejection, transplantation immunology
age difference, apoptosis, dosage, dosage forms, homologous transplantation, necrosis, pharmacokinetics, renal ischemia /hypoxia
animal tissue, dog, high throughput technology, laboratory rat
| Institution: | ANGION BIOMEDICA CORPORATION |
| 1050 Stewart Ave. |
| Garden City, NY 11530 |
| Fiscal Year: | 2007 |
| Department: | |
| Project Start: | 01-MAY-2004 |
| Project End: | 31-MAY-2008 |
| ICD: | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES |
| IRG: | ZRG1 |
|
